Who
Vincent Milano
Director
Company insider
Files Form 4 as: Director, BioCryst Pharmaceuticals; Director, Aclaris Therapeutics; President and CEO, Aceragen; Director, Spark Therapeutics; Director, Vanda Pharmaceuticals; President and CEO, Viropharma; Director, Verticalnet.
In numbers
- Trades disclosed
- 253
- Buys
- 8
- Sells
- 8
- Bought
- $1.2M
- Sold
- $4.0M
- Companies
- 7
- Companies where not an officer
- 5
- First trade
- 17 Jan 2006
- Last trade
- 31 Aug 2026
- Last filed
- 2 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Aug 2026filed 2 Sep 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $11K1,159 at $9.70 | filing |
| 31 Aug 2026filed 2 Sep 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $11K1,159 at $9.70 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —15,294 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,540 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,540 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —15,294 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,580 | filing |
| 5 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,580 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,580 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,580 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,350 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,987 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,350 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,987 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $9,9971,122 at $8.91 | filing |
| 29 May 2026filed 2 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $9,9971,122 at $8.91 | filing |
| 27 Feb 2026filed 3 Mar 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $7,420848 at $8.75 | filing |
| 27 Feb 2026filed 3 Mar 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $7,420848 at $8.75 | filing |
| 28 Nov 2025filed 2 Dec 2025 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $5,622783 at $7.18 | filing |
| 29 Aug 2025filed 3 Sep 2025 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $5,618676 at $8.31 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
Related people
Nobody else traded the same names lately.